Colorectal Cancer Therapeutics Market Size, Share, Analysis & Growth Report: 2015 - 2020 Edition

‘Colorectal Cancer (CRC) Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics’. The report, published by GBI research, is now available for sale on the GBI research website. The study provides exhaustive coverage of the market for colorectal cancer therapeutics in eight developed markets, namely, US, UK, Canada, Germany, France, Italy, Spain, and Japan. The report estimates the size of the colorectal cancer therapeutics market for 2013 and provides forecasts through 2020. The report also covers the epidemiology of the disease, its treatment algorithms and patterns, as well as an analysis of the current pipeline in great detail. The deals landscape of the colorectal cancer therapeutics market is assessed in detail.

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

According to the findings of the research, the CRC therapeutics market is expected to exhibit a CAGR of 1.8%, to touch US$9.4 billion by the end of 2020. Of all markets studied in this report, the United States was the leader in terms of market share as of 2013. In that year, the US’s share equaled 44.1% of the global market, followed at a distance by Japan (14.7%) and Germany (11.9%). At 4.1%, Spain carried the lowest share among the eight countries included in this report.

Japan will experience the fastest rate of growth—5%—among all other countries through the forecast period, the report states. However, Japan’s marginal growth rate will likely be stymied by aggressively-priced biosimilar versions of cetuximab and bevacizumab. This will occur primarily because the patents of Erbitux and Avastin are inching closer to expiration.

During the forecast period of the report, generic versions of the drug capecitabine are expected to be launched; ultimately impacting the market. However, some of this impact will be mitigated by certain emerging therapies—that are priced at a premium—on the horizon.

The team of analysts that produced this report found that the colorectal cancer therapeutics pipeline is teeming with potential drug candidates scattered across several clinical development phases. With approximately 400 molecules in the active pipeline, a preponderance of these drug candidates being investigated are being assessed for advanced-stage CRC – for both first- and second-line therapies.